Biofrontera Inc. 8-K

What Happened Biofrontera Inc. (BFRI) filed an 8-K on January 7, 2026 disclosing that on December 31, 2025 the Nasdaq Listing Qualifications Department notified the company that its common stock was not in compliance with Nasdaq Listing Rule 5550(a)(2) because the closing bid price was below $1.00 for 34 consecutive business days. The notice does not currently affect the listing or trading of the company’s shares. Under Nasdaq Rule 5810(c)(3)(A), Biofrontera has a 180-calendar-day compliance period — until June 30, 2026 — to regain compliance by achieving a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days.

Key Details

• Notice date from Nasdaq: December 31, 2025; 8-K filed January 7, 2026 (Item 3.01).
• Noncompliance reason: closing bid price below $1.00 for 34 consecutive business days (violates Rule 5550(a)(2)).
• Cure period: 180 calendar days ending June 30, 2026; must reach $1.00+ close for 10 consecutive business days to regain compliance.
• If not cured, the company may seek a second compliance period by meeting Nasdaq’s market value and other initial listing standards (except the minimum bid price) and by notifying Nasdaq and possibly effecting a reverse stock split; Nasdaq could also move to delist, subject to appeal.

Why It Matters A Nasdaq bid-price deficiency notice signals a material listing risk: if Biofrontera fails to regain the $1.00 minimum bid price within the cure periods, its shares could be delisted from Nasdaq, which can reduce liquidity and investor access. The company stated it will monitor the stock price and consider options to regain compliance, but warned there is no assurance it will succeed. Investors should be aware of the timeline (through June 30, 2026) and the potential for corporate actions (e.g., reverse split) or further Nasdaq proceedings if the issue is not resolved.